FORM 10-KSB
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
(Mark One)
[X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE
ACT OF 1934 For the fiscal year ended June 30, 2002
OR
[ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934 [NO FEE REQUIRED] for the transition period from
_______ to ______.
Commission file number 0-17449
PROCYON CORPORATION
(Name of small business issuer in its charter)
Colorado 59-3280822
(State or other jurisdiction of (I.R.S. Employer
incorporation or organization) Identification Number)
1150 Cleveland Street, Suite 410
Clearwater, Florida 33755
(Address of principal executive offices) (Zip Code)
Issuer's telephone number, including area code: (727) 447-2998
Securities registered pursuant to Section 12(b) of the Act:
None
Securities registered pursuant to section 12(g) of the Act:
Common Stock
[X] Check whether the registrant (1) filed all reports required to be filed by
Section 13 or 15(d) of the Securities Exchange Act of 1934 during the past 12
months (or for such shorter period that the registrant was required to file such
reports), and (2) has been subject to such filing requirements for the past 90
days.
[ ] Check if disclosure of delinquent filers in response to Item 405 of
Regulation S-B is not contained in this form, and no disclosure will be
contained, to the best of registrants knowledge, in definitive proxy or
information statements incorporated by reference in Part III of this Form 10-KSB
or any amendment to this Form 10-KSB.
State Issuer's revenues for its most recent fiscal year: $1,358,278
The aggregate market value of the 3,578,138 shares of Common Stock held by
non-affiliates was $2,844,620 on September 27, 2002 based on the average bid and
asked price of $.795 on such date. As of September 27, 2002, 7,894,338 shares of
the issuers Common Stock were outstanding.
DOCUMENTS INCORPORATED BY REFERENCE:
The information required by Part III of this annual report is incorporated by
reference to the registrants' definitive proxy statement if filed with the
Commission on or before October 28, 2002. If such proxy statement is not filed
by such date, the information required by Part III of this annual report will be
filed with the Commission as an amendment to this Form 10-KSB under cover of
Form 10-KSB/A, not later than October 28, 2002.
Transitional Small Business Disclosure Format: Yes [ ] No [X]
INDEX
Title Page
ITEM 1. DESCRIPTION OF BUSINESS.......................................... 3
ITEM 2. DESCRIPTION OF PROPERTY.......................................... 6
ITEM 3. LEGAL PROCEEDINGS................................................ 7
ITEM 4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS.............. 7
ITEM 5. MARKET FOR COMMON EQUITY AND RELATED STOCKHOLDER
MATTERS.......................................................... 7
ITEM 6. MANAGEMENT'S DISCUSSION AND ANALYSIS
OR PLAN OF OPERATION............................................. 9
ITEM 7. FINANCIAL STATEMENTS............................................. 11
ITEM 8. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON
ACCOUNTING AND FINANCIAL DISCLOSURE.............................. 12
ITEM 9. DIRECTORS, EXECUTIVE OFFICERS, PROMOTERS AND CONTROL
PERSONS; COMPLIANCE WITH SECTION 16(a) OF THE EXCHANGE
ACT ............................................................. 12
ITEM 10. EXECUTIVE COMPENSATION........................................... 12
ITEM 11. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND
MANAGEMENT....................................................... 13
ITEM 12. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS................... 13
ITEM 13. EXHIBITS AND REPORTS ON FORM 8-K................................. 13
2
Part I
ITEM 1. BUSINESS
History and Organization
Procyon Corporation (the "Company"), a Colorado corporation, was
incorporated on March 19, 1987 and was deemed a development stage company until
May 1996 when it acquired Amerx Health Care Corp. ("Amerx"), a corporation based
in Clearwater, Florida, which was wholly owned by John C. Anderson. Amerx
develops and markets proprietary medical products used in the treatment of
pressure ulcers, dermatitis, inflammation, and other skin problems. Sirius
Medical Supply ("Sirius"), a Florida corporation was formed in 2000 to operate
as a full service mail order medical supply company selling primarily to
Medicare and Medicaid customers. Amerx and Sirius are wholly owned subsidiaries
of Procyon Corporation. Historically, Amerx's products have been sold through
distributors to health care institutions, such as nursing homes and home health
care agencies, and to retailers, including national and regional chain stores
and pharmacies, while Sirius's products are sold directly to the consumer.
Products
Amerx's products currently consist of Amerigel(R) Hydrogel Wound Dressing,
Amerigel(R) Preventive Care Lotion, Amerigel(R) Preventive Barrier Lotion, and
Amerigel Wound Wash. The Amerigel(R) Hydrogel Wound Dressing is now formulated
to be used as a wound dressing to manage pressure ulcers stages I-IV, stasis
ulcers, diabetic skin ulcers, post surgical incisions, cuts, abrasions, 1st and
2nd degree burns, and skin irritations. The Amerigel(R) Preventive Care Lotion
has emollients, which restore moisture to fragile skin, protect the skin against
tears and chafing, and assist in prevention of chronic pressure ulcers. The
Amerigel(R) Barrier Lotion provides barrier protection to reduce the harmful
effects of urine and feces in incontinent patients. The Amerigel Wound Wash was
introduced as a wound cleanser that contains saline and Oakin. The industry
standard for wound cleansing has been saline, since tap water has chemicals and
additives that can be potentially harmful to a chronic wound.
Amerx also expects to introduce new products in fiscal 2003, provided the
funds necessary to manufacture and advertise these new products become
available. One of proposed products consists of two-inch and four-inch square
gauze sponges saturated with the Amerigel(R) Ointment Wound Dressing. The
sponges have been developed for packing deep wounds, and are expected to improve
healing. Other currently proposed new products include an acne cream and a
facial scrub. Amerx has not spent any funds on research and development efforts
during fiscal year 2002.
3
Management believes that each Amerx product is based on proprietary
formulations, which the Company has attempted to protect as trade secret
information. Each product is registered with the Food and Drug Administration
and receives a National Drug Code. In June 2002, the Company was granted a
Medicare Part B HCPCS Reimbursement Code ("Reimbursement Code") for its
Amerigel(R) Hydrogel Wound Dressing, which allows it to qualify for Medicare
reimbursements. The code granted to Amerx was the highest and fullest
reimbursement allowed for such products, and was obtained through significant
time and effort. With this new and final code, Amerx will be able to reintroduce
itself to the institutional market place. The Amerigel(R) Preventive Care Lotion
and the Amerigel(R) Barrier Lotion are not eligible for Medicare Part B
reimbursement as they are formulated for preventive maintenance care and as skin
protectants. Sales of the Company's wound care products currently represent
approximately 85% of net sales by the Company, while sales of the Companies
diabetic products represent approximately 13% of net sales.
Sirius's products at this time consist solely of diabetic supplies,
primarily glucose monitors, test strips, lancets, and syringes. Sirius is
building its customer base on these products with plans to expand into the
future with a broader product line to achieve its goal of becoming a full
service mail order medical supply company.
Market for Products
The institutional market for skin treatment products is comprised of
hospitals, nursing homes, home health care agencies and other health care
institutions that provide wound care to a large number of patients. Management
believes that Amerigel(R) products represent an inexpensive, yet effective,
treatment and prevention program for chronic pressure ulcers and other skin
problems, which are treated in health care institutions. Management believes
that obtaining the Reimbursement Code enhances Amerx's ability to offer
Amerigel(R) Hydrogel Wound Dressing to institutional entities such as nursing
homes and home health care agencies.
The retail market for skin care products is comprised mainly of mass
merchandise stores and pharmacies that sell such products to individuals for
personal use outside of health care facilities. The Company's products are
presently sold retail in independent pharmacies. The Company initiated a direct
response program and is now making direct retail sales to individual consumers
nationally.
The market for Sirius's products is comprised of diabetic patients who
receive benefits from Medicare or Medicaid, or from their insurance companies.
Sirius attracts these customers through advertising and direct marketing.
4
Sales and Marketing
The Company's traditional channel of distribution has been through retail
distributors. Management will continue to attempt to increase its distributor
base, particularly with distributors with an ability to introduce the Company's
products in new geographical areas and to new retail chains. Distributors
purchase products from the Company on standard credit terms. Product returns by
distributors are generally permitted only on dated products based upon a
two-year expiration date. The Company supports its distributors through product
literature, advertising and limited participation at industry trade shows. All
existing distributors sell Amerx products on a non-exclusive basis.
Sirius's channel of distribution is by mail order direct to consumers. The
Company has attracted and retained customers through marketing efforts. Sirius's
customer base is currently small. However, the Company believes it has
substantial potential, as there are over 17 million diabetics in the United
States, according to the American Diabetes Association.
The Company periodically has received inquiries about foreign market
distribution. These inquiries have been generated by the Company's advertising,
market presence and web sites (www.amerxhc.com and www.amerigel.com). The
Company intends to respond to and pursue all such inquiries.
Significant Customers
The Company expects that certain of its principal distributors may continue
to account for a significant portion of net sales, so the loss of any
significant distributor or customer could have an adverse effect on the
Company's future operating results and financial condition. The Company has been
able to maintain relationships with its distributors and has been able to
establish relationships with a few new distributors each year.
Manufacturing
All manufacturing and packaging activities are performed pursuant to
current good manufacturing practices ("CGMP") as defined under the United States
Federal Food, Drug and Cosmetic Act, as amended (the "Act"), and the regulations
promulgated under the Act. All manufacturing activities are required to comply
with the product specifications, supplies and test methods developed by Amerx
specifically for its products, as well as the CGMP, which apply to all
activities conducted by the manufacturer in the facility.
During fiscal 2002, manufacturing was completed by a small regional
company, which has in the past performed, and will in the future perform,
research and development activities for the Company. The Company does not have a
written contract with this manufacturer and there are no minimum purchase
agreements. Management believes there are other companies, which could
manufacture the Company's products current standard, if necessary. However, the
sudden loss or failure of this manufacturer could significantly impair Amerx's
ability to fulfill customer orders on a short-term basis.
5
One proprietary ingredient contained in all of the Company's products is
purchased and shipped to the manufacturing facility by the Company. The Company
does not have a written contract with the supplier of this ingredient and
management believes that an alternative supplier could be secured. Other raw
materials and ingredients are generally provided by the manufacturer and the
Company believes there are multiple suppliers of these materials and
ingredients. However, there is no guaranty that Amerx will find an alternative
supplier and the failure to replace a supplier could materially harm Amerx's
operations.
Proprietary Rights
In January 1999, the United States Patent and Trademark Office registered
the Company's Amerigel(R) trademark. The Company has made a trademark
application for the principal proprietary ingredient used in all of its
currently available products. The Company relies on a combination of trademark
and trade secret protection and confidentiality agreements to establish and
protect its proprietary rights.
Competition
The market for skin treatment products is highly competitive and
fragmented. Competition is intense and is based primarily on product efficacy,
brand recognition, loyalty, quality, price and availability of shelf space in
the retail market. The Company competes against several large well-capitalized
companies offering a broad range of skin treatment products as well as numerous
small competitors having a limited number of products. Many of these competitors
have longer operating histories, better name recognition and greater financial,
marketing and other resources than the Company. Because of the intense
competition and the Company's financial condition, there can be no assurance
that it will be able to increase its market share. The market for diabetic
supplies is also highly competitive, and Sirius will compete with other large
companies for market share.
Employees
As of September 30, 2002, the Company had twelve full-time employees,
consisting of four management employees, six sales-related employees and two
administrative employees. And one part-time employee.
ITEM 2. PROPERTIES
The Company currently maintains its offices at 1150 Cleveland Street, Suite
410, Clearwater, Florida 33755. The Company's offices consist of approximately
3,536 square feet of space, which is leased from an unrelated party. Management
believes the facility is adequate for the Company's current needs.
6
ITEM 3. LEGAL PROCEEDINGS
The Company is not a party to any pending material legal proceedings nor is
its property the subject of a pending legal proceeding.
ITEM 4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS.
No matter was submitted to a vote of security holders during the quarter
ended June 30, 2002.
Part II
ITEM 5. MARKET FOR COMPANY'S COMMON EQUITY AND RELATED STOCK MATTERS.
Since October 1996, the Company's Common Stock has traded on the OTC
Bulletin Board, an electronic quotation system used by members of the National
Association of Securities Dealers, Inc. The following table sets forth for each
period indicated the high and low closing bid prices for the Common Stock, as
reported by National Quotation Bureau, LLC. Bid quotations reflect interdealer
quotations, without retail markups, markdowns or commissions, and do not
necessarily reflect actual transactions.
Fiscal 2001 HIGH LOW
----------- ---- ---
First Quarter.................................. $1.0000 $ .5625
Second Quarter................................. .6875 .1875
Third Quarter.................................. .9375 .1875
Fourth Quarter................................. .6250 .2000
Fiscal 2002 HIGH LOW
----------- ---- ---
First Quarter.................................. $ .5000 $ .2000
Second Quarter................................. .2000 .0600
Third Quarter.................................. .2500 .0600
Fourth Quarter................................. .7500 .2500
As of September 25, 2002, there were approximately 147 record holders of
the Company's Common Stock. On September 25, 2002, the closing bid price of the
Company's common stock was $.71 and the closing ask price was $.88. On September
25, 2002, the last date on which a sale occurred, the last reported sale price
was $.75.
Holders of Common Stock are entitled to receive such dividends as may be
declared by the Company's Board of Directors. The Company has paid no dividends
on the Common Stock, nor does the Company anticipate that dividends on its
Common Stock will be paid in the foreseeable future.
Holders of the Preferred Stock are entitled to receive, if declared by the
Board of Directors, quarterly dividends at an annual rate of $.10 per share.
Dividends accrue without interest, are cumulative from the date of issuance, and
are payable in arrears in cash or common stock, when and if declared by the
Board of Directors. No dividends had been declared or paid at June 30, 2002 and
dividends in arrears at such date total approximately $147,651.
7
Holders of the Preferred Stock have the right to convert their shares of
Preferred Stock into an equal number of shares of Common Stock of the Company.
Such shares will automatically convert into one share of Common Stock at the
close of a public offering of Common Stock by the Company provided the Company
receives gross proceeds of at least $1,000,000, and the initial offering price
of the Common Stock sold in such offering is equal to or in excess of $1 per
share. During fiscal 2002, no holders of shares of Preferred Stock converted
their shares to Common Stock.
As reflected in the price quotations above, there have been significant
price fluctuations in the Company's Common Stock. Factors that may have caused
or can cause market prices to fluctuate include the number of shares available
in the public float, any purchase or sale of a significant number of shares
during a relatively short time period, quarterly fluctuations in results of
operations, issuance of additional securities, entrance of such securities into
the public float, market conditions specific to the Company's industry and
market conditions in general, and the willingness of broker-dealers to effect
transactions in low priced securities. In addition, in recent years the stock
market in general has experienced significant price and volume fluctuations.
These fluctuations, which may be unrelated to a Company's operating performance,
have had a substantial effect on the market price for many small capitalization
companies such as the Company. Factors such as those cited above, as well as
other factors that may be unrelated to the operating performance of the Company,
may adversely affect the price of the Common Stock.
Recent Sales of Unregistered Securities
The Company relied on Section 4(2) of the Securities Act of 1933, as
amended (the 1933 Act) for exemption from the registration requirements of
the1933 Act. All of the foregoing sales were made to officers and directors, or
to individuals or entities which had access to information enabling them to
evaluate the merits and risks of the investment by virtue of their relationship
to officers and directors of the Company or their economic bargaining power.
Each investor was furnished with information concerning the operations of the
Company and each had the opportunity to verify the information supplied.
Additionally, the Company obtained a signed representation from each of the
foregoing persons or entities of his or its intent to acquire the shares for the
purpose of investment only, and not with a view toward the subsequent
distribution thereof.
8
ITEM 6. MANAGEMENT'S DISCUSSION AND ANALYSIS OR PLAN OF OPERATION.
General
The continuing operations and revenues of the Company consist of the
operations of and revenues generated by Amerx and Sirius, the Company's two
wholly owned subsidiaries. Amerx's wound care and skin care products, marketed
under the trademark Amerigel(R), are formulated to enhance the quality of skin
and wound care and to lower the treatment cost of those who suffer from wound
and skin care problems. Sirius markets and distributes diabetic supplies via
mail order.
The Company markets Amerigel(R) products to institutional customers such as
nursing homes, hospitals and home health agencies and to retail customers.
Institutional sales are made either directly to the end user or through medical
supply distributors. Many institutional customers will not purchase directly
from the manufacturer; they will purchase products only through a national
distributor who warehouses the products and supplies the products directly to
the customer. Accordingly, the Company's products must be in the distributor's
warehouse in order for the Company to compete with other manufacturers. Amerx
reaches the retail consumer primarily through distributors, but in some cases,
through direct sales to a retail store chain. As of June 30, 2002, the Company's
skin care products were being distributed to institutions and to retail stores
through McKesson Drug, AmeriSource/Bergen Brunswig, Cardinal Health, Bindley
Western Drug and a number of smaller local and regional distributors.
Results of Operations
Comparison of Fiscal 2002 & 2001. Net sales during fiscal 2002 were
approximately $1,358,000 as compared to approximately $1,147,000 in fiscal 2001,
an increase of approximately $211,000, or 18%. Management believes that this
increase is attributable to its continuing marketing efforts, as well as a sales
price increase that began in January 2002.
Cost of sales decreased, to approximately $263,000 in 2002 as compared to
approximately $265,000 in 2001. Cost of sales remained consistent with the
previous year. Management believes that this was attributable to Sirius starting
to realize volume discounts.
Gross profit increased to approximately $1,096,000 during fiscal 2002 as
compared to approximately $882,000 during fiscal 2001, an increase of about
$214,000, or 24%. As a percentage of sales, gross profit was 81% in fiscal 2002,
as compared to 77% in fiscal 2001. This also was attributed to the sales price
increase in January of 2002, while cost remained at a consistent level.
Operating expenses during fiscal 2002 were approximately $1,197,000,
consisting of approximately $457,000 in salaries and benefits, $740,000 in
selling, general and administrative expenses. This represents a decrease in
expenses of approximately $377,000 as compared to expenses in fiscal 2001. As a
percentage of net sales, operating expenses during fiscal 2002 decreased to 88%,
as compared to 137% during fiscal 2001. Operating expenses for fiscal 2002 were
lower due to the events of September 11, 2001. The Company was forced to
restructure its marketing campaigns, as marketing results diminished for the
remainder of 2001.
9
Loss from operations decreased to approximately $101,000 in 2002, as
compared to approximately $692,000 in fiscal 2001. Net loss (after dividend
requirements for Preferred Shares) was approximately $167,000 during fiscal
2002, compared to approximately $700,000 during fiscal 2001.
As of June 30, 2002, the Company had a deferred tax asset of approximately
$1,404,000, consisting primarily of net operating losses. The Company recorded a
valuation allowance equal to 100 percent of the deferred tax asset, as the
Company was unable to determine that it was more likely than not the deferred
tax asset will be realized. The valuation allowance decreased approximately
$380,000 from fiscal 2001 to 2002.
Liquidity and Capital Resources
Historically, the Company has financed its operations through a combination
of revenues from operations, shareholder loans, and the public sales of equity.
As of June 30, 2002, the Company's principal sources of liquidity included
inventories of approximately $57,000, and net accounts receivable of
approximately $110,000. The Company had negative working capital of
approximately $364,000 and long-term debt of approximately $16,000 at June 30,
2002.
Operating activities used cash of approximately $217,000 during fiscal 2002
and approximately $486,000 during fiscal 2001, consisting primarily of net
losses of approximately $138,000 and $687,000, respectively. Cash used in
investing activities during fiscal 2002 and 2001 was approximately $7,000 and
$50,000, respectively. Cash provided by financing activities during fiscal 2002
and 2001 was approximately $205,000 and $75,000, respectively. There were no
sales of Preferred Stock in fiscal 2002 or 2001.
At June 30, 2002 the Company had no commitments for capital expenditures.
During fiscal 2002, no holders of shares of Preferred Stock converted their
shares to Common Stock.
The Company's financial statements have been prepared assuming that the
Company will continue as a going concern. The Company has incurred losses since
its inception and has been dependent upon equity financing and shareholder loans
to fund working capital needs. The accompanying financial statements do not
include any adjustments that might result from the determination of this
uncertainty.
The Safe Harbor Statement under the Private Securities Litigation Reform Act of
1995
This Report on Form 10-KSB, including Management's Discussion and Analysis
or Plan of Operation, contains forward-looking statements. When used in this
report, the words "may," "will," "expect," "anticipate," "continue," "estimate,"
"project," "intend," "believe" and similar expressions, variations of these
words or the negative of those word are intended to identify forward-looking
statements within the meaning of Section 27A of the Securities Act of 1933 and
Section 21E of the Securities Exchange Act of 1934 regarding events, conditions
and financial trends including, without limitation, business conditions in the
skin and wound care market and the general economy, competitive factors, changes
in product mix, production delays, manufacturing capabilities, and other risks
or uncertainties detailed in other of the Company's Securities and Exchange
Commission filings. Such statements are based on management's current
expectations and are subject to risks, uncertainties and assumptions. Should one
or more of these risks or uncertainties materialize, or should underlying
assumptions prove incorrect, the Company's actual plan of operations, business
strategy, operating results and financial position could differ materially from
those expressed in, or implied by, such forward-looking statements.
10
ITEM 7. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA
Consolidated Financial Statements as of June 30, 2002 and 2001 were audited
by Ferlita, Walsh & Gonzalez P.A., the Company's independent auditors, as
indicated in their report included appearing at page F-1.
11
INDEX TO FINANCIAL STATEMENTS
-----------------------------
Page
----
Report of Independent Certified Public Accountants......................... F-1
Consolidated Balance Sheet June 30, 2002................................... F-2
Consolidated Statements of Operations For the Years Ended
June 30, 2002 and 2001..................................................... F-3
Consolidated Statements of Stockholders' Deficiency For the
Years Ended June 30, 2002 and 2001......................................... F-4
Consolidated Statements of Cash Flows For the Years Ended
June 30, 2002 and 2001..................................................... F-5
Notes to Financial Statements.............................................. F-6
ITEM 8. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND
FINANCIAL DISCLOSURE.
During the two preceding fiscal years, there were no disagreements with the
Company's auditors on any matters of accounting principles or practices,
financial statement disclosure, or auditing scope of procedure that would have
caused the Company's accountants to make reference to such agreements in
connection with their report.
PART III
Certain information required by Part III is omitted from this Report in that the
Registrant will file a definite proxy statement pursuant to Regulation 14A (the
"Proxy Statement") not later than 120 days after the end of the fiscal year
covered by this report and certain information included therein is incorporated
herein by reference. Only those sections of the Proxy Statement that
specifically address the items set forth herein are incorporated by reference.
ITEM 9. DIRECTORS, EXECUTIVE OFFICERS, PROMOTERS AND CONTROL PERSONS; COMPLIANCE
WITH SECTION 16(a) OF THE EXCHANGE ACT OF THE REGISTRANT.
The information required by this Item is incorporated by reference to the
Company's Proxy Statement.
ITEM 10. EXECUTIVE COMPENSATION.
The information required by this Item is incorporated by reference to the
Company's Proxy Statement.
12
ITEM 11. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT.
The information required by this Item is incorporated by reference to the
Company's Proxy Statement.
ITEM 12. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS.
The information required by this Item is incorporated by reference to the
Company's Proxy Statement.
ITEM 13. EXHIBITS AND REPORTS ON FORM 8-K.
(a) Exhibits
--------
1. The financial statements filed herewith are listed in the Index to
Financial Statements included in Item 7.
Reg. S-B
Exhibit No. Document Item No.
----------- -------- --------
* 3.1 Articles of Incorporation 3
+ 3.1.1 Articles of Amendment to Articles of Incorporation 3
* 3.2 Bylaws 3
+ 4.1 Designation of Series A Preferred Stock 4
+ 10.4 Loan and Security Agreement, dated as of January 1,
1995, by and between the Company and Amerx Health Care
Corp., including Promissory Notes issued there under. 10
o 10.4 Agreement and Plan of Exchange, dated January 31, 1996,
by and between the Company and Amerx. 10
x 99.1 Certification Pursuant to 18 U.S.C.ss.1350, as Adopted
Pursuant to Section 906 of the Sarbanes-Oxley Act Of
2002 99
* Incorporated by reference to the Company's Registration Statement on Form
S-1, S.E.C. File No. 33-13273.
+ Incorporated by reference to the Company's Form 10-KSB for the fiscal year
ended June 30, 1995.
o Incorporated by reference to the Company's Form 8-K filed on or about
February 2, 1996.
x Filed herewith.
(b) Reports on Form 8-K
-------------------
None.
13
ITEM 14. CONTROLS AND PROCEDURES
During fiscal 2002, the Company did not institute any significant changes
in its internal controls. In addition, there were no significant changes in
other factors that could significantly affect these controls.
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on
its behalf by the undersigned, thereunto duly authorized.
PROCYON CORPORATION
By: /s/ John C. Anderson
------------------------
John C. Anderson, President and
acting Principal Executive,
Financial and Accounting Officer
Date: September 27, 2002
Pursuant to the requirements of the Securities Exchange Act of 1934, this
report has been signed below by the following persons on behalf of the
registrant and in the capacities and on the dates indicated.
Signature Title Date
--------- ----- ----
/s/ John C. Anderson President and Acting September 27, 2002
-------------------- Principal Executive, Financial
John C. Anderson and Accounting Officer
/s/ Chester L. Wallack Director September 27, 2002
----------------------
Chester L. Wallack
/s/ Fred W. Suggs, Jr. Director September 27, 2002
----------------------
Fred W. Suggs, Jr.
/s/ Alan B. Crane Director September 27, 2002
-----------------
Alan B. Crane
/s/ Richard T. Thompson Director September 27, 2002
-----------------------
Richard T. Thompson
/s/ Jeffery S. Slowgrove Director September 27, 2002
------------------------
Jeffery S. Slowgrove
14
CERTIFICATION
I, John C. Anderson, President and acting Principal Executive, Financial and
Accounting Officer of Procyon Corporation, certify that:
1. I have reviewed this annual report on Form 10-K of Procyon Corporation;
2. Based on my knowledge, this annual report does not contain any untrue
statement of a material fact or omit to state a material fact necessary to make
the statements made, in light of the circumstances under which such statements
were made, not misleading with respect to the period covered by this annual
report; and
3. Based on my knowledge, the financial statements, and other financial
information included in this annual report, fairly present in all material
respects the financial condition, results of operations and cash flows of the
registrant as of, and for, the periods presented in this annual report.
Date: September 27, 2002
/s/ JOHN C. ANDERSON
--------------------
John C. Anderson
President and acting Principal Executive,
Financial and Accounting Officer
EXHIBIT INDEX
-------------
Reg. S-B
Exhibit No. Document Item No.
----------- -------- --------
* 3.1 Articles of Incorporation 3
+ 3.1.1 Articles of Amendment to Articles of Incorporation 3
* 3.2 Bylaws 3
+ 4.1 Designation of Series A Preferred Stock 4
+ 10.4 Loan and Security Agreement, dated as of January 1,
1995, by and between the Company and Amerx Health Care
Corp., including Promissory Notes issued there under. 10
o 10.4 Agreement and Plan of Exchange, dated January 31, 1996,
by and between the Company and Amerx. 10
x 99.1 Certification Pursuant to 18 U.S.C.ss.1350, as Adopted
Pursuant to Section 906 of the Sarbanes-Oxley Act Of
2002 99
* Incorporated by reference to the Company's Registration Statement on Form
S-1, S.E.C. File No. 33-13273.
+ Incorporated by reference to the Company's Form 10-KSB for the fiscal year
ended June 30, 1995.
o Incorporated by reference to the Company's Form 8-K filed on or about
February 2, 1996.
x Filed herewith.
PROCYON CORPORATION AND SUBSIDIARIES
CONSOLIDATED FINANCIAL STATEMENTS
Years Ended June 30, 2002 and 2001
TABLE OF CONTENTS
Page No.
--------
REPORT OF INDEPENDENT CERTIFIED PUBLIC ACCOUNTANTS....................... F-1
FINANCIAL STATEMENTS
Consolidated Balance Sheet............................................. F-2
Consolidated Statements of Operations.................................. F-3
Consolidated Statements of Stockholders' Deficiency.................... F-4
Consolidated Statements of Cash Flows.................................. F-5
Notes to Financial Statements.......................................... F-6
REPORT OF INDEPENDENT CERTIFIED PUBLIC ACCOUNTANTS
Board of Directors
Procyon Corporation and Subsidiaries
Clearwater, Florida
We have audited the accompanying consolidated balance sheet of Procyon
Corporation and Subsidiaries as of June 30, 2002 and the related statements of
operations, stockholders' deficiency, and cash flows for the years ended June
30, 2002 and 2001. These financial statements are the responsibility of the
Company's management. Our responsibility is to express an opinion on these
financial statements based on our audits.
We conducted our audits in accordance with auditing standards generally accepted
in the United States of America. Those standards require that we plan and
perform the audit to obtain reasonable assurance about whether the financial
statements are free of material misstatement. An audit includes examining, on a
test basis, evidence supporting the amounts and disclosures in the financial
statements. An audit also includes assessing the accounting principles used and
significant estimates made by management, as well as evaluating the overall
financial statement presentation. We believe that our audits provide a
reasonable basis for our opinion.
In our opinion, the financial statements referred to above present fairly, in
all material respects, the financial position of Procyon Corporation and
Subsidiaries as of June 30, 2002 and the results of its operations and its cash
flows for the years ended June 30, 2002 and 2001, in conformity with accounting
principles generally accepted in the United States of America.
/s/ FERLITA, WALSH & GONZALEZ, P.A.
-----------------------------------
FERLITA, WALSH & GONZALEZ, P.A.
Certified Public Accountants
Tampa, Florida
August 9, 2002
F-1
PROCYON CORPORATION AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEET
June 30, 2002
ASSETS
CURRENT ASSETS
Accounts receivable, less allowance
of $8,500 for doubtful accounts $ 109,985
Prepaid expense 35,283
Inventories 57,303
-----------
TOTAL CURRENT ASSETS 202,571
PROPERTY AND EQUIPMENT
Office equipment 59,794
Furniture and fixtures 14,666
Production equipment 14,236
-----------
88,696
Accumulated depreciation (49,355)
-----------
39,341
OTHER ASSETS
Deposits 844
Certificates of deposit plus accrued interest, restricted 17,114
-----------
17,958
-----------
$ 259,870
===========
LIABILITIES AND STOCKHOLDERS' DEFICIENCY
CURRENT LIABILITIES
Excess of checks issued over bank balance $ 24,168
Current portion of long-term debt 5,499
Accounts payable 249,370
Accrued expenses 29,774
Note payable to stockholders 258,487
-----------
TOTAL CURRENT LIABILITIES 567,298
LONG-TERM DEBT 16,238
STOCKHOLDERS' DEFICIENCY
Preferred stock, 496,000,000 shares authorized;
none issued 0
Series A cumulative convertible preferred stock
no par value; 4,000,000 shares authorized;
288,600 shares issued and outstanding 244,450
Common stock, no par value, 80,000,000 shares
authorized; 7,840,338 shares issued and outstanding 4,262,414
Accumulated deficit (4,830,530)
-----------
(323,666)
-----------
$ 259,870
===========
The accompanying notes are an integral part of these financial statements.
F-2
PROCYON CORPORATION AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF OPERATIONS
Years Ended June 30, 2002 and 2000
2002 2001
----------- -----------
NET SALES $ 1,358,278 $ 1,146,799
COST OF SALES 262,639 265,061
----------- -----------
GROSS PROFIT 1,095,639 881,738
OPERATING EXPENSES
Salaries and benefits 456,720 442,986
Selling, general and administrative 740,294 1,130,695
----------- -----------
1,197,014 1,573,681
----------- -----------
LOSS FROM OPERATIONS (101,375) (691,943)
OTHER INCOME (EXPENSE)
Other income 446 0
Interest income 580 9,161
Interest expense (37,562) (3,904)
----------- -----------
(36,536) 5,257
----------- -----------
NET LOSS (137,911) (686,686)
Dividend requirements on preferred stock (28,860) (13,203)
----------- -----------
Loss applicable to common stock $ (166,771) $ (699,889)
=========== ===========
Net loss per common share $ (0.02) $ (0.09)
=========== ===========
Weighted average number of common
shares outstanding 7,815,973 7,815,973
=========== ===========
The accompanying notes are an integral part of these financial statements.
F-3
PROCYON CORPORATION AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF STOCKHOLDERS' DEFICIENCY
Years Ended June 30, 2002 and 2001
Preferred Stock Common Stock
-------------------------- ------------------------- Accumulated
Shares Amount Shares Amount Deficit Total
----------- ----------- ----------- ----------- ----------- -----------
Balance, June 30, 2000 368,133 $ 323,983 7,760,805 $ 4,182,881 $(4,005,933) $ 500,931
Conversion of preferred stock
to common stock (79,533) (79,533) 79,533 79,533 0 0
Net loss 0 0 0 0 (686,686) (686,686)
----------- ----------- ----------- ----------- ----------- -----------
Balance, June 30, 2001 288,600 244,450 7,840,338 4,262,414 (4,692,619) (185,755)
Net loss 0 0 0 0 (137,911) (137,911)
----------- ----------- ----------- ----------- ----------- -----------
Balance, June 30, 2002 288,600 $ 244,450 7,840,338 $ 4,262,414 $(4,830,530) $ (323,666)
=========== =========== =========== =========== =========== ===========
The accompanying notes are an integral part of these financial statements.
F-4
PROCYON CORPORATION AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CASH FLOWS
Years Ended June 30, 2002 and 2001
2002 2001
--------- ---------
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss $(137,911) $(686,686)
Adjustments to reconcile net loss to
net cash used by operating activities:
Depreciation 13,170 9,862
Allowance for doubtful accounts 8,000 0
Accrued interest on certificate of deposit 459 (573)
Decrease (increase) in:
Accounts receivable (48,170) (53,126)
Inventory (12,570) 14,333
Prepaid expenses (16,141) 2,432
Other assets 676 9,653
Increase (decrease) in:
Excess of checks issued over bank balance 24,168 0
Accounts payable (21,124) 193,212
Accrued expenses (27,868) 25,313
--------- ---------
NET CASH USED BY
OPERATING ACTIVITIES (217,311) (485,580)
CASH FLOWS FROM INVESTING ACTIVITIES
Proceeds from disposition of property and equipment 1,982 0
Purchase of certificates of deposit 0 (17,000)
Purchase of property and equipment (8,994) (32,655)
--------- ---------
NET CASH USED BY
INVESTING ACTIVITIES (7,012) (49,655)
CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from stockholder loan 183,487 75,000
Proceeds from long term loan 25,000 0
Repayment of long term loan (3,263) 0
--------- ---------
NET CASH PROVIDED BY
FINANCING ACTIVITIES 205,224 75,000
--------- ---------
NET DECREASE IN CASH (19,099) (460,235)
CASH AT BEGINNING OF PERIOD 19,099 479,334
--------- ---------
CASH AT END OF PERIOD $ 0 $ 19,099
========= =========
SUPPLEMENTAL DISCLOSURES
Taxes Paid $ 0 $ 0
Interest Paid $ 37,562 $ 3,904
NONCASH TRANSACTIONS DISCLOSURE:
Conversion of Series A cumulative convertible preferred stock to common stock $ 0 $ 79,533
The accompanying notes are an integral part of these financial statements.
F-5
PROCYON CORPORATION AND SUBSIDIARIES
NOTES TO FINANCIAL STATEMENTS
NOTE A - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Business Activity
-----------------
Procyon Corporation has two wholly-owned subsidiaries, Amerx Health Care Corp
(Amerx) and Sirius Medical Supplies, Inc. (Sirius). Amerx manufactures and
markets wound care and skin care products in the United States whereas Sirius
markets diabetic supplies to patients in the United States.
Principles of Consolidation
---------------------------
The consolidated financial statements include the accounts of Procyon
Corporation and its wholly-owned subsidiaries, Amerx Health Care Corp and Sirius
Medical Supply, Inc. All material intercompany accounts and transactions are
eliminated.
Use of Estimates
----------------
The preparation of financial statements in conformity with accounting principles
generally accepted in the United States of America requires management to make
estimates and assumptions that affect the reported amounts of assets and
liabilities, the disclosure of contingent assets and liabilities at the date of
the financial statements, and the reported amounts of revenues and expenses
during the reporting period. Actual results could differ from those estimates.
Cash and Cash Equivalents
-------------------------
For the purpose of the Statements of Cash Flows, the Company considers
cash-on-hand, demand deposits in banks and highly liquid investments purchased
with an original maturity of three months or less to be cash equivalents.
The Company has classified the certificates of deposits as restricted assets.
These certificates of deposits are collateral on a letter of credit issued by a
financial institution and therefore are not available for operations.
Concentrations of Credit Risk
-----------------------------
Financial instruments which potentially subject the Company to concentrations of
credit risk consist primarily of cash and cash equivalents. The Company places
its cash and cash equivalents in one financial institution. The Federal Deposit
Insurance Corporation (FDIC) insures cash and cash equivalents deposited at a
financial institution for up to $100,000. The Company did not have any uninsured
cash and cash equivalents at June 30, 2002.
Amerx grants credit to customers most of whom are national pharmaceutical
companies, nationwide drug stores and physicians. Amerx wholesales its products
to national pharmaceutical companies and nationwide drug stores at a sales term
of 2/10, net 30. Amerx does not have a written return policy with these
customers. Each return request is reviewed by management prior to its approval.
Sales to physicians and patients are at retail and standard payment term is 30
days.
Sirius grants credit to physicians and patients who are eligible for Medicare
coverage. Sales are at standard payment term of 30 days.
Management deems that an allowance for doubtful accounts of $8,500 is adequate
based upon its review of its receivables and its collection experience.
Inventories
-----------
Inventories are valued at the lower of weighted average cost or market
determined by the first-in, first-out method.
Property and Equipment
----------------------
Property and equipment are stated at cost. Depreciation is computed on a
straight-line basis over the estimated useful life of 5 years.
F-6
PROCYON CORPORATION AND SUBSIDIARIES
NOTES TO FINANCIAL STATEMENTS
Revenue Recognition
-------------------
Revenue is recognized upon the shipment of goods to customers and when title
passes to the customers.
Shipping and Handling Costs
---------------------------
Shipping and handling costs incurred were $78,000 and $104,000 for the years
ended June 30, 2002 and 2001, respectively and are included in selling, general
and administrative expenses.
Advertising and Marketing
-------------------------
In accordance with Statement of Position 93-7, Reporting on Advertising Costs,
advertising costs are to be expensed except for direct-response advertising (1)
whose primary purpose is to elicit sales to customers who could be shown to have
responded specifically to the advertising and (2) that results in probable
future economic benefits. In order to determine whether such advertisements
generate probable future economic benefits, the Company must establish
historical patterns of responses to the direct-response advertising. Management
believes that there is insufficient history to evaluate the future economic
benefits from direct-response advertising. Therefore, all advertising costs
incurred are expensed. During the years ended June 30, 2002 and 2001,
approximately $367,000 and $ 744,000 of advertising costs are included in
selling, general and administrative expense.
Income Taxes
------------
The Company accounts for income taxes under Statement of Financial Accounting
Standards No. 109, "Accounting for Income Taxes" ("SFAS 109"). SFAS 109 requires
the recognition of deferred tax assets and liabilities for the expected future
tax consequences of events that have been included in the financial statements
or tax returns. Under this method, deferred tax assets and liabilities are
determined based on the differences between the financial statement and the tax
basis of assets and liabilities using enacted tax rates currently in effect.
Net Loss Per Share
------------------
Net loss per share is based on the weighted average number of shares outstanding
during each period presented. Outstanding stock rights are included as common
stock equivalents, when dilutive.
Fair Value of Financial Instruments
-----------------------------------
The carrying value of cash, accounts receivable, deposits, inventory, accounts
payable, and accrued expenses approximate fair value. Note payable to related
party is discussed in Note D.
Considerable judgement is required in interpreting market data to develop the
estimates of fair value, and, accordingly, the estimates are not necessarily
indicative of the amounts that the Company could realize in a current market
exchange.
NOTE B - GOING CONCERN
As reflected in the accompanying financial statements, the Company has a deficit
in stockholders' equity of $323,666 at June 30, 2002 and has incurred net losses
of $137,911 and $686,686 for the years ended June 30, 2002 and 2001,
respectively. In addition, net cash used in operations was $217,311 and $485,580
for the years ended June 30, 2002 and 2001, respectively. Such operating cash
deficiency in fiscal year 2002 has been funded through the Company's line of
credit with its major shareholder. Operating cash deficiency in fiscal year 2001
has been funded through proceeds from private offerings during fiscal 2001 and
funds from the Company's line of credit with its major shareholder.
F-7
PROCYON CORPORATION AND SUBSIDIARIES
NOTES TO FINANCIAL STATEMENTS
Management of the Company has developed and implemented a plan to reduce its
operating expenses. The Company expects to raise approximately $240,000 for
operations through the issuance of additional shares of common stock upon
exercising options issued under the 1998 Omnibus Stock Option Plan subsequent to
year end. The ability of the Company to continue as a going concern is dependent
upon the availability of funds through its majority stockholder, its ability to
generate sales to cover its operating costs as well as the success to raise
funds for future operations. The financial statements do not include any
adjustments that might be necessary if the Company is unable to continue as a
going concern.
NOTE C - INVENTORIES
Inventories consisted of the following:
June 30,
2002
-------
Finished Goods $ 4,563
Raw Materials 42,235
Diabetic Products 10,505
-------
$57,303
=======
NOTE D - RELATED PARTY TRANSACTIONS
The majority shareholder and President of the Company has a $300,000 line of
credit with a financial institution, collateralized by his personal residence.
The line of credit is renewed annually. The majority shareholder of the Company
extended the line of credit to the Company during the year at 8% interest per
annum. At June 30, 2002, the majority shareholder was owed $258,487 on the line
of credit.
The Company has an unsecured note payable with one of its officers. The note
calls for monthly payments to the officer of approximately $683 at an interest
rate of 14% per annum. At June 30, 2002, the balance of the note was $21,737.
See NOTE F - LONG-TERM DEBT for additional disclosure.
NOTE E - COMMITMENTS AND CONTINGENCIES
The Company leases certain equipment under various operating leases expiring in
year 2006. The minimum lease payment due under the lease agreements for fiscal
years ended June 30 is as follow:
June 30,
-------
2003 $ 7,080
2004 7,080
2005 7,080
2006 7,080
2007 and thereafter 5,604
-------
$33,924
=======
The Company also leased its warehouse and office on a month-to-month basis. Rent
expense for the years ended June 30, 2002 and 2001 was approximately $48,000 and
$33,000, respectively.
F-8
PROCYON CORPORATION AND SUBSIDIARIES
NOTES TO FINANCIAL STATEMENTS
NOTE F - LONG-TERM DEBT
Long-term debt consists of a note payable with one of the Company's officers.
The note calls for monthly payment of approximately $683 at an interest rate of
14% per annum. The amount due in the next five years ending June 30 is as
follow:
2003 $ 5,499
2004 6,319
2005 7,264
2006 2,655
--------
21,737
Less: current portion (5,499)
--------
$ 16,238
========
NOTE G - STOCKHOLDERS' DEFICIENCY
During January 1995, the Company's Board of Directors authorized the issuance of
up to 4,000,000 shares of Series A Cumulative Convertible Preferred Stock. The
preferred stockholders are entitled to receive, if declared by the board of
directors, quarterly dividends at an annual rate of $.10 per share of Series A
Cumulative Convertible Preferred Stock per annum. Dividends accrue without
interest and are cumulative from the date of issuance of the Series A Cumulative
Convertible Preferred Stock and are payable quarterly in arrears in cash or
publicly traded common stock when and if declared by the board of directors. As
of June 30, 2002, no dividends have been declared. Dividends in arrears on the
outstanding preferred shares total $147,651 or $0.51 per share as of June 30,
2002. The preferred stockholders have the right to convert each share of Series
A Cumulative Convertible Preferred Stock into one share of the Company's common
stock at any time without additional consideration. Each share of Series A
Cumulative Convertible Preferred Stock is subject to mandatory conversion into
one share of common stock of the Company, effective as of the close of a public
offering of the Company's common stock provided, however, that the offering must
provide a minimum of $1 million in gross proceeds to the Company and the initial
offering price of such common stock must be at least $1 per share. In addition
to the rights described above, the holders of the Series A Cumulative
Convertible Preferred Stock have voting rights equal to the common stockholders
based upon the number of shares of common stock into which the Series A
Cumulative Convertible Preferred Stock is convertible. The Company is obligated
to reserve an adequate number of shares of its common stock to satisfy the
conversion of all of the outstanding Series A Cumulative Convertible Preferred
Stock.
NOTE H - INCOME TAXES AND AVAILABLE CARRYFORWARDS
The Company's deferred tax asset at June 30, 2002 consists primarily of the tax
benefit of net operating loss carryforwards amounting to approximately
$1,404,000. The Company has recorded a valuation allowance equal to 100 percent
of the deferred tax asset as the Company was unable to determine that it is more
likely than not that the deferred tax asset will be realized. The valuation
allowance decreased approximately $380,000 from June 30, 2001 to 2002. At June
30, 2002, for income tax purposes, the Company had net operating loss
carryforwards of approximately $4,871,000 which expire on various dates through
2022.
NOTE I - CONCENTRATION OF RISK
The Company's manufacturing and packaging activities are performed at a
production facility owned and operated by a nonaffiliated pharmaceutical
manufacturer. At the present time, the manufacturer is the sole source of the
Company's wound care products. However, the Company has maintained a long-term
relationship with this manufacturer and does not expect a discontinuance of its
wound care products from the manufacturer in the short term.
F-9
PROCYON CORPORATION AND SUBSIDIARIES
NOTES TO FINANCIAL STATEMENTS
NOTE J - EMPLOYEE INCENTIVE PLAN
In December, 1998, the Company adopted a 1998 Omnibus Stock Option Plan that
provides for the granting of equity-based incentive and other awards to
employees and directors of the Company, its subsidiaries and selected
consultants. The Plan is administered by the Compensation Committee of the Board
of Directors. Any employee, directors who are not employees of the Corporation
or a subsidiary, and consultants who are not employees or directors of the
Corporation are eligible to participate in the Plan. The maximum number of
shares of common stock issuable on exercise of options or other awards granted
under the Plan is 1,000,000. Non-qualified options granted must have an exercise
price not less than 85% of the fair market value of the underlying shares of
common stock. Incentive options must have an exercise price not less than 100%
of the fair market value of the underlying shares of common stock. The term of
the options cannot be more than ten years. Awards may be granted in the form of
restricted stock. Awards can also be granted in the form of stock appreciation
rights. A stock appreciation right entitles the participant to receive from the
Company an amount equal to the positive difference between the fair market value
of common stock on the date of exercise of the stock appreciation right and the
grant price. No stock appreciation rights have been issued to date pending a
resolution by the Board of Directors on earning requirements.
Additional information with respect to the Plan's stock option activity is as
follows:
Weighted
Number of Average
Shares Exercise Price
------- --------------
Outstanding at June 30, 2000 235,000 $ 0.21
Granted 65,000 $ 0.16
Exercised -- --
Cancelled -- --
-------
Outstanding at June 30, 2001 300,000 $ 0.20
Granted -- --
Exercised -- --
Cancelled -- --
-------
Outstanding at June 30, 2002 300,000 $ 0.20
======= ======
Option exercisable at June 30, 2001 300,000 $ 0.20
======= ======
Option exercisable at June 30, 2002 300,000 $ 0.20
======= ======
F-10
PROCYON CORPORATION AND SUBSIDIARIES
NOTES TO FINANCIAL STATEMENTS
The following table summarizes information about stock options outstanding and
exercisable at June 30, 2002:
Stock Options
Outstanding
---------------------------------------------
Weighted Average
Number of Remaining Weighted
Range of Shares Contractual Life Average
Exercise Prices Outstanding In Years Exercise Price
--------------- ----------- ---------------- --------------
$0.15 - $0.20 65,000 7.51 $0.16
$0.20 - $0.25 235,000 8.39 $0.21
-------
300,000 7.70 $0.20
======= ==== =====
The Company has elected to follow APB Opinion No. 25 "Accounting for Stock
Issued to Employees" in accounting for its employee stock options. Accordingly,
no compensation expense is recognized in the Company's financial statements. If
under Financial Accounting Standards Board Statement No. 123 "Accounting for
Stock-Based Compensation", the Company determined compensation costs based on
the fair value at the grant date for its stock options, net loss and loss per
share would have been increased to the following pro forma amounts:
2002 2001
---------- ----------
Net (loss) applicable to common stock:
As reported $ (137,911) $ (805,477)
Pro forma $ (137,911) $ (817,664)
Basic and diluted (loss) per common share:
As reported $ (0.04) $ (0.10)
Pro forma $ (0.04) $ (0.10)
The weighted average estimated fair value of stock options granted during the
year ended June 30, 2001 was $0.19. There were no options issued during fiscal
year ended June 30, 2002. These amounts were determined using the Black-Scholes
option-pricing model, which values options based on the stock price at the grant
date, the expected dividend payments, and the risk-free interest rate over the
life of the option. The assumptions used in the Black-Scholes model were as
follows for stock options granted in the years ended June 30:
2002 2001
----------------------------- --------
Risk-free interest rate 5.29%
There were no options granted
during this fiscal year.
Expected volatility of common stock 297%
Dividend yield 0%
Expected life of options 10 years
F-11
PROCYON CORPORATION AND SUBSIDIARIES
NOTES TO FINANCIAL STATEMENTS
The Black-Scholes option valuation model was developed for estimating the fair
value of traded options that have no vesting restrictions and are fully
transferable. Because option valuation models require the use of subjective
assumptions, changes in these assumptions can materially affect the fair value
of the options. The Company's options do not have the characteristics of traded
option, therefore, the option valuation models do not necessarily provide a
reliable measure of the fair value of its options.
NOTE K - SEGMENT INFORMATION
The Company operates in the following two business segments:
1. Sale of wound care products - Amerx Health Care operates in the sale of
ointment and wound care products segment. The marketing of these products
targets primarily to diabetic patients who have difficulties providing
proper care and treatment of wounds due to their diabetic condition and
podiatrists who recommend the products to their patients.
2. Sale of diabetic supplies - Sirius Medical Supplies provides meters, test
strips, monitors, syringes, etc. primarily to diabetic patients. The
Company is then reimbursed by Medicare and/or secondary insurance.
Each separately managed segment offers different products requiring different
marketing and distribution strategies.
Revenues Information
Wound Care Diabetic
June 30, Products Products Other Consolidated
-------- -------- -------- ----- ------------
Revenues 2002 $1,167,651 $171,036 $19,591 $1,358,278
2001 1,073,572 39,474 33,748 1,146,794
Segment
Gross Profit 2002 1,009,387 86,141 112 1,095,640
2001 895,492 18,059 2,944 916,495
Identifiable Assets 2002 152,749 75,453 -- 228,202
2001 157,829 39,390 20,161 217,380
Property and Equipment
Additions 2002 8,995 -- -- 8,995
2001 29,539 3,116 -- 32,655
Depreciation 2002 11,092 623 1,455 13,170
2001 8,226 181 1,455 9,862
Geographical Information
The Company operates and sells its products to its customers within the United
States. All assets are located within the United States.
F-12
PROCYON CORPORATION AND SUBSIDIARIES
NOTES TO FINANCIAL STATEMENTS
NOTE L - RECENT ACCOUNTING PRONOUNCEMENTS
In December 2000, the Securities and Exchange Commission ("SEC") issued Staff
Accounting Bulletin No. 101, "Revenue Recognition in Financial Statements" (SAB
101), subsequently updated by SAB 101B. SAB 101 and SAB 101B summarize certain
of the Staff's views in applying generally accepted accounting principles to
revenue recognition in financial statements. The Company is required to adopt
SAB 101 no later than the fourth quarter of fiscal year 2002. The effects of
applying this guidance, if any, will be reported as a cumulative effect
adjustment resulting from a change in accounting principle. The adoption of SAB
101 is not expected to have a material impact on its financial position or
results of operations.
The Financial Accounting Standards Board (FASB) issued Statement No. 141,
"Business Combinations" ("SFAS 141") for all business combinations initiated
after June 30, 2001. This standard requires that all business combinations be
accounted for using the purchase method, and it further clarifies the criteria
for recognition of intangible assets separately from goodwill. Since June 30,
2001, there have been no business combinations.
In June, 2001, the Financial Accounting Standards Board (FASB) issued Statement
No. 142, "Goodwill and Other Intangible Assets" ("SFAS 142"). This Statement
addresses financial accounting and reporting for acquired goodwill and other
intangible assets and supersedes APB Opinion No. 17, "Intangible Assets". It
addresses how intangible assets that are acquired individually or with a group
of other assets (but not those acquired in a business combination) should be
accounted for in financial statements upon their acquisition. This Statement
also addresses how goodwill and other intangible assets should be accounted for
after they have been initially recognized in the financial statements. The
Company has reviewed the Statement and does not expect it will have a material
impact on its financial position and results of operations.
In June, 2001, the Financial Accounting Standards Board (FASB) issued Statement
No. 143, "Accounting for Asset Retirement Obligations" ("SFAS 143"). This
Statement addresses financial accounting and reporting for obligations
associated with the retirement of tangible long-lived assets and the associated
asset retirement costs. This Statement applies to all entities. It applies to
legal obligations associated with the retirement of long-lived assets that
result from the acquisition, construction, development and (or) the normal
operation of a long-lived asset, except for certain obligations of lessees. As
used in this Statement, a legal obligation is an obligation that a party is
required to settle as a result of an existing or enacted law, statute,
ordinance, or written or oral contract or by legal construction of a contract
under the doctrine of promissory estoppel. This Statement amends FASB Statement
No. 19, "Financial Accounting and Reporting by Oil and Gas Producing Companies".
The Company has reviewed the Statement and does not expect it will have a
material impact on its financial position and results of operations.
In August, 2001, the Financial Accounting Standards Board (FASB) issued
Statement No. 144, "Accounting for the Impairment or Disposal of Long-Lived
Assets" ("SFAS 144"). This Statement retains the requirements of Statement 121
to recognize an impairment loss only of the carrying amount of a long-lived
asset is not recoverable from its undiscounted cash flows and measure an
impairment loss as the difference between the carrying amount and fair value of
the asset. The Statement removes goodwill from its scope and, therefore,
eliminates the requirement of Statement 121 to allocate goodwill to long-lived
assets to be tested for impairment. The Company has reviewed the Statement and
does not expect it will have a material impact on its financial position and
results of operations.
In April, 2002, the Financial Accounting Standards Board (FASB) issued Statement
No. 145, "Recission of FAS No. 4, "Reporting Gains and Losses from
Extinguishment of Debt", No. 44, "Accounting for Intangible Assets for Motor
Carriers" and No. 64, "Extinguishment of Debt Made to Satisfy Sinking-Fund
Requirements". This Statement also amends FAS No. 13, " Accounting for Leases"
and Technical Corrections" ("SFAS 145"). The Company has reviewed the Statement
and does not expect it will have a material impact on its financial position and
results of operations.
NOTE M - SUBSEQUENT EVENT (UNAUDITED)
Subsequent to year end, the Company granted options with an exercise price of
$0.60 per share for 200,000 shares, and $1.60 for 75,000 shares.
F-13